Lakewood-Amedex Biotherapeutics (LABT)

• Market cap: $51.3M
• 1 day: -50.2%
• 5 days: -54.25%
• 1 month: -57.69%
• 3 months: -57.69%
• 6 months: -57.69%
• Year to date: -57.69%
• 1 year: -57.69%
• 5 years: -57.69%
• 10 years: -57.69%
• Sector: Healthcare
• Industry: Biotechnology

About: Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.